

*COUP-TF.*

*b13  
b*

2. The method of claim 1 wherein the adenovirus packaging repressor is COUP-TF.

3. The method of claim 1 wherein the adenovirus packaging repressor is *lac* repressor.

4. The method according to claim 1 wherein the propagating step occurs in a first cell line and the packaging repressing step occurs in a second cell line.

5. The method according to claim 1 wherein the packaging repressing step occurs in a cell line coinfecting with a vector expressing the adenovirus packaging repressor.

6. An adenovirus vector comprising an adenovirus packaging sequence containing a plurality of COUP-TF binding sites comprising an A repeat VI element.

7. An adenovirus vector comprising an adenovirus packaging sequence having at least two copies of 5'-TTTGN<sub>8</sub>CG-3' and a plurality of COUP-TF binding sites, comprising an A repeat VI element.

9. A method of administering adenovirus comprising the steps of:

- encapsidating the adenovirus vector of claim 8, thereby forming an adenovirus;
- isolating said adenovirus;
- preparing said adenovirus in a pharmaceutically acceptable carrier;
- administering said adenovirus to a mammal.

10. An adenovirus vector containing a packaging signal sequence consisting of at least two copies of 5'-TTTGN<sub>8</sub>CG-3' and an A repeat VI element.

*Sub 4*  
11. An adenovirus vector according to claim 10 wherein an adenovirus packaging repressor binding site is embedded in the packaging signal sequence.

*Sub 2*  
12. An adenovirus vector according to claim 10 wherein an adenovirus packaging repressor binding site flanks the packaging signal sequence.

*Sub 3*  
13. An adenovirus vector according to claim 10 wherein an adenovirus packaging repressor binding site alternates with the packaging signal sequence.

*Sub 4*  
15. An adenovirus vector according to claim 14 wherein an adenovirus packaging repressor binding site is located between packaging signal sequences.

*Sub 3*  
16. An adenovirus vector according to claim 11 or 15 wherein the adenovirus packaging repressor binding site is a *lac* repressor site.

17. An adenovirus vector according to claim 11 or 15 wherein the adenovirus packaging repressor binding site is a E2F binding site.

*Sub 3 15*  
19. A method of administering adenovirus comprising the steps of:  
a. encapsidating the adenovirus vector of claim 10, thereby forming an adenovirus;  
b. isolating said adenovirus  
c. preparing said adenovirus in a pharmaceutically acceptable carrier;  
and  
d. administering said adenovirus to a mammal.